You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcetyldigitoxin
Accession NumberDB00511  (APRD01334)
TypeSmall Molecule
GroupsApproved
DescriptionCardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Structure
Thumb
Synonyms
Acetildigitoxina
Acetyl-digitoxin-alpha
Acetyldiginatin
Acetyldigitoxinum
Acetylgitaloxin
Acetylgitoxin
alpha-Acetyldigitoxin
alpha-Acetylgitaloxin
alpha-Monoacetyldigitoxin
Desglucolanatoside A
Digitoxin 3'''-acetate
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0ZV4Q4L2FU
CAS number1111-39-3
WeightAverage: 806.9757
Monoisotopic: 806.44525682
Chemical FormulaC43H66O14
InChI KeyInChIKey=HPMZBILYSWLILX-UMDUKNJSSA-N
InChI
InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1
IUPAC Name
(2R,3R,4S,6S)-3-hydroxy-6-{[(2R,3S,4S,6S)-4-hydroxy-6-{[(2R,3S,4S,6R)-4-hydroxy-6-{[(1S,2S,5S,7R,10R,11S,14R,15R)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-4-yl acetate
SMILES
[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[[email protected]](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[[email protected]]3C[[email protected]](OC(C)=O)[[email protected]](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • Oxane
  • 2-furanone
  • Acetate salt
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed for fast digitalization in congestive heart failure.
PharmacodynamicsThe main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na+/K+ ATPase pump.
Mechanism of actionAcetyldigitoxin binds to a site on the extracellular aspect of the α-subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias.
Related Articles
AbsorptionBioavailability is 60 to 80% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityToxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9781
Blood Brain Barrier+0.6297
Caco-2 permeable-0.8308
P-glycoprotein substrateSubstrate0.833
P-glycoprotein inhibitor IInhibitor0.7038
P-glycoprotein inhibitor IIInhibitor0.7664
Renal organic cation transporterNon-inhibitor0.8236
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateNon-substrate0.9191
CYP450 3A4 substrateSubstrate0.7356
CYP450 1A2 substrateNon-inhibitor0.9105
CYP450 2C9 inhibitorNon-inhibitor0.9065
CYP450 2D6 inhibitorNon-inhibitor0.9544
CYP450 2C19 inhibitorNon-inhibitor0.9516
CYP450 3A4 inhibitorNon-inhibitor0.8311
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9302
Ames testNon AMES toxic0.9072
CarcinogenicityNon-carcinogens0.9603
BiodegradationNot ready biodegradable0.9769
Rat acute toxicity4.6091 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Inhibitor0.6255
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility0.0274 mg/L at 25 °CMEYLAN,WM et al. (1996)
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0123 mg/mLALOGPS
logP2.87ALOGPS
logP4.04ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)7.18ChemAxon
pKa (Strongest Basic)0.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area188.9 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity200.87 m3·mol-1ChemAxon
Polarizability87.95 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideAcetyldigitoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolAcetyldigitoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol.
3-MethoxybenzamideAcetyldigitoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide.
3,4-Dihydroxybenzoic AcidAcetyldigitoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.
5,10-Dideazatetrahydrofolic AcidAcetyldigitoxin may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineAcetyldigitoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.
8-azaguanineAcetyldigitoxin may decrease the cardiotoxic activities of 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineAcetyldigitoxin may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneAcetyldigitoxin may decrease the cardiotoxic activities of Abiraterone.
ABT-263Acetyldigitoxin may decrease the cardiotoxic activities of ABT-263.
AcebutololAcebutolol may increase the bradycardic activities of Acetyldigitoxin.
AfatinibAcetyldigitoxin may decrease the cardiotoxic activities of Afatinib.
AfimoxifeneAcetyldigitoxin may decrease the cardiotoxic activities of Afimoxifene.
AfliberceptAcetyldigitoxin may decrease the cardiotoxic activities of Aflibercept.
AlatrofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.
AlbendazoleAcetyldigitoxin may decrease the cardiotoxic activities of Albendazole.
AldesleukinAcetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.
AlemtuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Alemtuzumab.
AlitretinoinAcetyldigitoxin may decrease the cardiotoxic activities of Alitretinoin.
Alpha-DifluoromethylornithineAcetyldigitoxin may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.
AlprenololAlprenolol may increase the bradycardic activities of Acetyldigitoxin.
AltretamineAcetyldigitoxin may decrease the cardiotoxic activities of Altretamine.
AmikacinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Amikacin.
AmilorideThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Amiloride.
AminoglutethimideAcetyldigitoxin may decrease the cardiotoxic activities of Aminoglutethimide.
Aminolevulinic acidAcetyldigitoxin may decrease the cardiotoxic activities of Aminolevulinic acid.
AmiodaroneThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amiodarone.
AmodiaquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amodiaquine.
AmonafideAcetyldigitoxin may decrease the cardiotoxic activities of Amonafide.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.
AmrubicinAcetyldigitoxin may decrease the cardiotoxic activities of Amrubicin.
AmsacrineAcetyldigitoxin may decrease the cardiotoxic activities of Amsacrine.
AnagrelideAcetyldigitoxin may decrease the cardiotoxic activities of Anagrelide.
AnastrozoleAcetyldigitoxin may decrease the cardiotoxic activities of Anastrozole.
annamycinAcetyldigitoxin may decrease the cardiotoxic activities of annamycin.
AP 12009Acetyldigitoxin may decrease the cardiotoxic activities of AP 12009.
AP24534Acetyldigitoxin may decrease the cardiotoxic activities of AP24534.
ArotinololArotinolol may increase the bradycardic activities of Acetyldigitoxin.
Arsenic trioxideAcetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.
ASA404Acetyldigitoxin may decrease the cardiotoxic activities of ASA404.
AsparaginaseAcetyldigitoxin may decrease the cardiotoxic activities of Asparaginase.
AT-101Acetyldigitoxin may decrease the cardiotoxic activities of AT-101.
AtenololAtenolol may increase the bradycardic activities of Acetyldigitoxin.
AxitinibAcetyldigitoxin may decrease the cardiotoxic activities of Axitinib.
AzacitidineAcetyldigitoxin may decrease the cardiotoxic activities of Azacitidine.
AzathioprineAcetyldigitoxin may decrease the cardiotoxic activities of Azathioprine.
AZD2171Acetyldigitoxin may decrease the cardiotoxic activities of AZD2171.
Azelaic AcidAcetyldigitoxin may decrease the cardiotoxic activities of Azelaic Acid.
BalsalazideThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide.
BatimastatAcetyldigitoxin may decrease the cardiotoxic activities of Batimastat.
BefunololBefunolol may increase the bradycardic activities of Acetyldigitoxin.
BelinostatAcetyldigitoxin may decrease the cardiotoxic activities of Belinostat.
BendamustineAcetyldigitoxin may decrease the cardiotoxic activities of Bendamustine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acetyldigitoxin.
BesifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Besifloxacin.
BetaxololBetaxolol may increase the bradycardic activities of Acetyldigitoxin.
BevacizumabAcetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.
BevantololBevantolol may increase the bradycardic activities of Acetyldigitoxin.
BexaroteneAcetyldigitoxin may decrease the cardiotoxic activities of Bexarotene.
BicalutamideAcetyldigitoxin may decrease the cardiotoxic activities of Bicalutamide.
BisoprololBisoprolol may increase the bradycardic activities of Acetyldigitoxin.
BleomycinAcetyldigitoxin may decrease the cardiotoxic activities of Bleomycin.
BlinatumomabAcetyldigitoxin may decrease the cardiotoxic activities of Blinatumomab.
BopindololBopindolol may increase the bradycardic activities of Acetyldigitoxin.
BortezomibAcetyldigitoxin may decrease the cardiotoxic activities of Bortezomib.
BosutinibAcetyldigitoxin may decrease the cardiotoxic activities of Bosutinib.
Brentuximab vedotinAcetyldigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.
BSI-201Acetyldigitoxin may decrease the cardiotoxic activities of BSI-201.
BufuralolBufuralol may increase the bradycardic activities of Acetyldigitoxin.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin.
BupranololBupranolol may increase the bradycardic activities of Acetyldigitoxin.
BusulfanAcetyldigitoxin may decrease the cardiotoxic activities of Busulfan.
CabazitaxelAcetyldigitoxin may decrease the cardiotoxic activities of Cabazitaxel.
CabergolineAcetyldigitoxin may decrease the cardiotoxic activities of Cabergoline.
CabozantinibAcetyldigitoxin may decrease the cardiotoxic activities of Cabozantinib.
CalcipotriolAcetyldigitoxin may decrease the cardiotoxic activities of Calcipotriol.
CamptothecinAcetyldigitoxin may decrease the cardiotoxic activities of Camptothecin.
CapecitabineAcetyldigitoxin may decrease the cardiotoxic activities of Capecitabine.
CarbimazoleThe serum concentration of Acetyldigitoxin can be increased when it is combined with Carbimazole.
CarboplatinAcetyldigitoxin may decrease the cardiotoxic activities of Carboplatin.
CarfilzomibAcetyldigitoxin may decrease the cardiotoxic activities of Carfilzomib.
CarmofurAcetyldigitoxin may decrease the cardiotoxic activities of Carmofur.
CarmustineAcetyldigitoxin may decrease the cardiotoxic activities of Carmustine.
CarteololCarteolol may increase the bradycardic activities of Acetyldigitoxin.
CarvedilolCarvedilol may increase the bradycardic activities of Acetyldigitoxin.
CatumaxomabAcetyldigitoxin may decrease the cardiotoxic activities of Catumaxomab.
CB1954Acetyldigitoxin may decrease the cardiotoxic activities of CB1954.
CelecoxibAcetyldigitoxin may decrease the cardiotoxic activities of Celecoxib.
CeliprololCeliprolol may increase the bradycardic activities of Acetyldigitoxin.
CeritinibAcetyldigitoxin may decrease the cardiotoxic activities of Ceritinib.
CetuximabAcetyldigitoxin may decrease the cardiotoxic activities of Cetuximab.
ChlorambucilAcetyldigitoxin may decrease the cardiotoxic activities of Chlorambucil.
ChloroquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin.
ChlorotrianiseneAcetyldigitoxin may decrease the cardiotoxic activities of Chlorotrianisene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetyldigitoxin.
CholestyramineCholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinAcetyldigitoxin may decrease the cardiotoxic activities of Cinoxacin.
CiprofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Ciprofloxacin.
CisplatinAcetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.
CladribineAcetyldigitoxin may decrease the cardiotoxic activities of Cladribine.
ClofarabineAcetyldigitoxin may decrease the cardiotoxic activities of Clofarabine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.
ColchicineAcetyldigitoxin may decrease the cardiotoxic activities of Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CrizotinibAcetyldigitoxin may decrease the cardiotoxic activities of Crizotinib.
CyclophosphamideAcetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.
Cyproterone acetateAcetyldigitoxin may decrease the cardiotoxic activities of Cyproterone acetate.
CytarabineAcetyldigitoxin may decrease the cardiotoxic activities of Cytarabine.
DabrafenibAcetyldigitoxin may decrease the cardiotoxic activities of Dabrafenib.
DacarbazineAcetyldigitoxin may decrease the cardiotoxic activities of Dacarbazine.
DactinomycinAcetyldigitoxin may decrease the cardiotoxic activities of Dactinomycin.
DaratumumabAcetyldigitoxin may decrease the cardiotoxic activities of Daratumumab.
DasatinibAcetyldigitoxin may decrease the cardiotoxic activities of Dasatinib.
DaunorubicinAcetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin.
DaunorubicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Daunorubicin.
DecitabineAcetyldigitoxin may decrease the cardiotoxic activities of Decitabine.
Denileukin diftitoxAcetyldigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.
DexamethasoneAcetyldigitoxin may decrease the cardiotoxic activities of Dexamethasone.
DexrazoxaneAcetyldigitoxin may decrease the cardiotoxic activities of Dexrazoxane.
DienogestAcetyldigitoxin may decrease the cardiotoxic activities of Dienogest.
DiethylstilbestrolAcetyldigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.
DihydrostreptomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Dihydrostreptomycin.
DinutuximabAcetyldigitoxin may decrease the cardiotoxic activities of Dinutuximab.
DocetaxelAcetyldigitoxin may decrease the cardiotoxic activities of Docetaxel.
DoxorubicinAcetyldigitoxin may decrease the cardiotoxic activities of Doxorubicin.
DoxorubicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Doxorubicin.
EcabetAcetyldigitoxin may decrease the cardiotoxic activities of Ecabet.
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.
efaproxiralAcetyldigitoxin may decrease the cardiotoxic activities of efaproxiral.
EflornithineAcetyldigitoxin may decrease the cardiotoxic activities of Eflornithine.
EG009Acetyldigitoxin may decrease the cardiotoxic activities of EG009.
ElsamitrucinAcetyldigitoxin may decrease the cardiotoxic activities of Elsamitrucin.
EndostatinAcetyldigitoxin may decrease the cardiotoxic activities of Endostatin.
EnoxacinAcetyldigitoxin may decrease the cardiotoxic activities of Enoxacin.
EnrofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Enrofloxacin.
EpirubicinAcetyldigitoxin may decrease the cardiotoxic activities of Epirubicin.
EpirubicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Epirubicin.
EplerenoneThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Eplerenone.
Epothilone BAcetyldigitoxin may decrease the cardiotoxic activities of Epothilone B.
EribulinAcetyldigitoxin may decrease the cardiotoxic activities of Eribulin.
ErlotinibAcetyldigitoxin may decrease the cardiotoxic activities of Erlotinib.
EsmololEsmolol may increase the bradycardic activities of Acetyldigitoxin.
EstramustineAcetyldigitoxin may decrease the cardiotoxic activities of Estramustine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.
Ethiodized oilAcetyldigitoxin may decrease the cardiotoxic activities of Ethiodized oil.
Ethyl carbamateAcetyldigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.
EtoposideAcetyldigitoxin may decrease the cardiotoxic activities of Etoposide.
EverolimusAcetyldigitoxin may decrease the cardiotoxic activities of Everolimus.
ExemestaneAcetyldigitoxin may decrease the cardiotoxic activities of Exemestane.
exisulindAcetyldigitoxin may decrease the cardiotoxic activities of exisulind.
FenretinideAcetyldigitoxin may decrease the cardiotoxic activities of Fenretinide.
FlavopiridolAcetyldigitoxin may decrease the cardiotoxic activities of Flavopiridol.
FleroxacinAcetyldigitoxin may decrease the cardiotoxic activities of Fleroxacin.
FloxuridineAcetyldigitoxin may decrease the cardiotoxic activities of Floxuridine.
FludarabineAcetyldigitoxin may decrease the cardiotoxic activities of Fludarabine.
FlumequineAcetyldigitoxin may decrease the cardiotoxic activities of Flumequine.
FluorouracilAcetyldigitoxin may decrease the cardiotoxic activities of Fluorouracil.
FlutamideAcetyldigitoxin may decrease the cardiotoxic activities of Flutamide.
FormestaneAcetyldigitoxin may decrease the cardiotoxic activities of Formestane.
FormycinAcetyldigitoxin may decrease the cardiotoxic activities of Formycin.
FotemustineAcetyldigitoxin may decrease the cardiotoxic activities of Fotemustine.
FramycetinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Framycetin.
FulvestrantAcetyldigitoxin may decrease the cardiotoxic activities of Fulvestrant.
FumagillinAcetyldigitoxin may decrease the cardiotoxic activities of Fumagillin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin.
Gallium nitrateAcetyldigitoxin may decrease the cardiotoxic activities of Gallium nitrate.
GarenoxacinAcetyldigitoxin may decrease the cardiotoxic activities of Garenoxacin.
GatifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Gatifloxacin.
GefitinibAcetyldigitoxin may decrease the cardiotoxic activities of Gefitinib.
GeldanamycinAcetyldigitoxin may decrease the cardiotoxic activities of Geldanamycin.
GemcitabineAcetyldigitoxin may decrease the cardiotoxic activities of Gemcitabine.
GemifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Gemifloxacin.
Gemtuzumab ozogamicinAcetyldigitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.
GenisteinAcetyldigitoxin may decrease the cardiotoxic activities of Genistein.
GentamicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin.
Ginsenoside CAcetyldigitoxin may decrease the cardiotoxic activities of Ginsenoside C.
GoserelinAcetyldigitoxin may decrease the cardiotoxic activities of Goserelin.
GrepafloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Grepafloxacin.
HadacidinAcetyldigitoxin may decrease the cardiotoxic activities of Hadacidin.
HalofuginoneAcetyldigitoxin may decrease the cardiotoxic activities of Halofuginone.
HexestrolAcetyldigitoxin may decrease the cardiotoxic activities of Hexestrol.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin.
HydroxychloroquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Hydroxychloroquine.
Hydroxyprogesterone caproateAcetyldigitoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.
HydroxyureaAcetyldigitoxin may decrease the cardiotoxic activities of Hydroxyurea.
Hygromycin BThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Hygromycin B.
IbrutinibAcetyldigitoxin may decrease the cardiotoxic activities of Ibrutinib.
IdarubicinAcetyldigitoxin may decrease the cardiotoxic activities of Idarubicin.
IdarubicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Idarubicin.
IdelalisibAcetyldigitoxin may decrease the cardiotoxic activities of Idelalisib.
IfosfamideAcetyldigitoxin may decrease the cardiotoxic activities of Ifosfamide.
ImatinibAcetyldigitoxin may decrease the cardiotoxic activities of Imatinib.
ImiquimodAcetyldigitoxin may decrease the cardiotoxic activities of Imiquimod.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin.
IndenololIndenolol may increase the bradycardic activities of Acetyldigitoxin.
Interferon beta-1aAcetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.
IobenguaneAcetyldigitoxin may decrease the cardiotoxic activities of Iobenguane.
IpilimumabAcetyldigitoxin may decrease the cardiotoxic activities of Ipilimumab.
IrinotecanAcetyldigitoxin may decrease the cardiotoxic activities of Irinotecan.
ItraconazoleThe serum concentration of Acetyldigitoxin can be increased when it is combined with Itraconazole.
IxabepiloneAcetyldigitoxin may decrease the cardiotoxic activities of Ixabepilone.
IxazomibAcetyldigitoxin may decrease the cardiotoxic activities of Ixazomib.
KanamycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Kanamycin.
KaolinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Kaolin.
KOS-1584Acetyldigitoxin may decrease the cardiotoxic activities of KOS-1584.
L-alanosineAcetyldigitoxin may decrease the cardiotoxic activities of L-alanosine.
LabetalolLabetalol may increase the bradycardic activities of Acetyldigitoxin.
LanreotideAcetyldigitoxin may decrease the cardiotoxic activities of Lanreotide.
LapatinibAcetyldigitoxin may decrease the cardiotoxic activities of Lapatinib.
LeflunomideAcetyldigitoxin may decrease the cardiotoxic activities of Leflunomide.
LenalidomideAcetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.
LenvatinibAcetyldigitoxin may decrease the cardiotoxic activities of Lenvatinib.
LetrozoleAcetyldigitoxin may decrease the cardiotoxic activities of Letrozole.
LeuprolideAcetyldigitoxin may decrease the cardiotoxic activities of Leuprolide.
LevobunololLevobunolol may increase the bradycardic activities of Acetyldigitoxin.
LevofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Levofloxacin.
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Acetyldigitoxin.
LomefloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Lomefloxacin.
LomustineAcetyldigitoxin may decrease the cardiotoxic activities of Lomustine.
LonidamineAcetyldigitoxin may decrease the cardiotoxic activities of Lonidamine.
LycopeneAcetyldigitoxin may decrease the cardiotoxic activities of Lycopene.
MasitinibAcetyldigitoxin may decrease the cardiotoxic activities of Masitinib.
MasoprocolAcetyldigitoxin may decrease the cardiotoxic activities of Masoprocol.
MaxacalcitolAcetyldigitoxin may decrease the cardiotoxic activities of Maxacalcitol.
MDX-1106Acetyldigitoxin may decrease the cardiotoxic activities of MDX-1106.
MebendazoleAcetyldigitoxin may decrease the cardiotoxic activities of Mebendazole.
MechlorethamineAcetyldigitoxin may decrease the cardiotoxic activities of Mechlorethamine.
MedrogestoneAcetyldigitoxin may decrease the cardiotoxic activities of Medrogestone.
Medroxyprogesterone acetateAcetyldigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Megestrol acetateAcetyldigitoxin may decrease the cardiotoxic activities of Megestrol acetate.
MelphalanAcetyldigitoxin may decrease the cardiotoxic activities of Melphalan.
MequinolAcetyldigitoxin may decrease the cardiotoxic activities of Mequinol.
MercaptopurineAcetyldigitoxin may decrease the cardiotoxic activities of Mercaptopurine.
MesalazineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Mesalazine.
MethimazoleThe serum concentration of Acetyldigitoxin can be increased when it is combined with Methimazole.
MethotrexateAcetyldigitoxin may decrease the cardiotoxic activities of Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin.
Methyl aminolevulinateAcetyldigitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.
MethylprednisoloneAcetyldigitoxin may decrease the cardiotoxic activities of Methylprednisolone.
MethyltestosteroneAcetyldigitoxin may decrease the cardiotoxic activities of Methyltestosterone.
MetipranololMetipranolol may increase the bradycardic activities of Acetyldigitoxin.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin.
MetoprololMetoprolol may increase the bradycardic activities of Acetyldigitoxin.
MetrizamideThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Metrizamide.
MGI-114Acetyldigitoxin may decrease the cardiotoxic activities of MGI-114.
MidodrineAcetyldigitoxin may increase the bradycardic activities of Midodrine.
MidostaurinAcetyldigitoxin may decrease the cardiotoxic activities of Midostaurin.
MiltefosineAcetyldigitoxin may decrease the cardiotoxic activities of Miltefosine.
MitomycinAcetyldigitoxin may decrease the cardiotoxic activities of Mitomycin.
MitotaneAcetyldigitoxin may decrease the cardiotoxic activities of Mitotane.
MitoxantroneAcetyldigitoxin may decrease the cardiotoxic activities of Mitoxantrone.
motexafin gadoliniumAcetyldigitoxin may decrease the cardiotoxic activities of motexafin gadolinium.
MoxifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Moxifloxacin.
Mycophenolic acidAcetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.
NadololNadolol may increase the bradycardic activities of Acetyldigitoxin.
Nalidixic AcidAcetyldigitoxin may decrease the cardiotoxic activities of Nalidixic Acid.
NecitumumabAcetyldigitoxin may decrease the cardiotoxic activities of Necitumumab.
NelarabineAcetyldigitoxin may decrease the cardiotoxic activities of Nelarabine.
NeomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Neomycin.
NetilmicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Netilmicin.
NiguldipineAcetyldigitoxin may decrease the cardiotoxic activities of Niguldipine.
NilotinibAcetyldigitoxin may decrease the cardiotoxic activities of Nilotinib.
NilutamideAcetyldigitoxin may decrease the cardiotoxic activities of Nilutamide.
NintedanibAcetyldigitoxin may decrease the cardiotoxic activities of Nintedanib.
NivolumabAcetyldigitoxin may decrease the cardiotoxic activities of Nivolumab.
nocodazoleAcetyldigitoxin may decrease the cardiotoxic activities of nocodazole.
NorfloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Norfloxacin.
ObinutuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Obinutuzumab.
OctreotideAcetyldigitoxin may decrease the cardiotoxic activities of Octreotide.
OfatumumabAcetyldigitoxin may decrease the cardiotoxic activities of Ofatumumab.
OfloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Ofloxacin.
OlaparibAcetyldigitoxin may decrease the cardiotoxic activities of Olaparib.
OlsalazineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine.
Omacetaxine mepesuccinateAcetyldigitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
OprelvekinAcetyldigitoxin may decrease the cardiotoxic activities of Oprelvekin.
OsimertinibAcetyldigitoxin may decrease the cardiotoxic activities of Osimertinib.
OxaliplatinAcetyldigitoxin may decrease the cardiotoxic activities of Oxaliplatin.
OxprenololOxprenolol may increase the bradycardic activities of Acetyldigitoxin.
PaclitaxelAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel.
PalbociclibAcetyldigitoxin may decrease the cardiotoxic activities of Palbociclib.
PalifosfamideAcetyldigitoxin may decrease the cardiotoxic activities of Palifosfamide.
PamidronateAcetyldigitoxin may decrease the cardiotoxic activities of Pamidronate.
PanitumumabAcetyldigitoxin may decrease the cardiotoxic activities of Panitumumab.
PanobinostatAcetyldigitoxin may decrease the cardiotoxic activities of Panobinostat.
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Acetyldigitoxin.
ParomomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Paromomycin.
PazopanibAcetyldigitoxin may decrease the cardiotoxic activities of Pazopanib.
PefloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Pefloxacin.
PegaspargaseAcetyldigitoxin may decrease the cardiotoxic activities of Pegaspargase.
PembrolizumabAcetyldigitoxin may decrease the cardiotoxic activities of Pembrolizumab.
PemetrexedAcetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed.
PenbutololPenbutolol may increase the bradycardic activities of Acetyldigitoxin.
PentostatinAcetyldigitoxin may decrease the cardiotoxic activities of Pentostatin.
PertuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Pertuzumab.
Phenylacetic acidAcetyldigitoxin may decrease the cardiotoxic activities of Phenylacetic acid.
PindololPindolol may increase the bradycardic activities of Acetyldigitoxin.
PipobromanAcetyldigitoxin may decrease the cardiotoxic activities of Pipobroman.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigitoxin.
PirfenidoneAcetyldigitoxin may decrease the cardiotoxic activities of Pirfenidone.
PirlindoleAcetyldigitoxin may decrease the cardiotoxic activities of Pirlindole.
PixantroneAcetyldigitoxin may decrease the cardiotoxic activities of Pixantrone.
PlicamycinAcetyldigitoxin may decrease the cardiotoxic activities of Plicamycin.
PlicamycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Plicamycin.
PodofiloxAcetyldigitoxin may decrease the cardiotoxic activities of Podofilox.
PodophyllinAcetyldigitoxin may decrease the cardiotoxic activities of Podophyllin.
polyacrylic acidAcetyldigitoxin may decrease the cardiotoxic activities of polyacrylic acid.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Acetyldigitoxin.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Acetyldigitoxin.
PomalidomideAcetyldigitoxin may decrease the cardiotoxic activities of Pomalidomide.
PonatinibAcetyldigitoxin may decrease the cardiotoxic activities of Ponatinib.
PorfimerAcetyldigitoxin may decrease the cardiotoxic activities of Porfimer.
porfiromycinAcetyldigitoxin may decrease the cardiotoxic activities of porfiromycin.
PractololPractolol may increase the bradycardic activities of Acetyldigitoxin.
PralatrexateAcetyldigitoxin may decrease the cardiotoxic activities of Pralatrexate.
PrednisoloneAcetyldigitoxin may decrease the cardiotoxic activities of Prednisolone.
PrednisoneAcetyldigitoxin may decrease the cardiotoxic activities of Prednisone.
PrimaquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Primaquine.
ProcarbazineAcetyldigitoxin may decrease the cardiotoxic activities of Procarbazine.
PropafenoneThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the bradycardic activities of Acetyldigitoxin.
PropylthiouracilThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propylthiouracil.
Purine RibosideAcetyldigitoxin may decrease the cardiotoxic activities of Purine Riboside.
PuromycinAcetyldigitoxin may decrease the cardiotoxic activities of Puromycin.
PuromycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Puromycin.
QuinacrineAcetyldigitoxin may decrease the cardiotoxic activities of Quinacrine.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Acetyldigitoxin.
QuinidineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Quinidine.
Radium Ra 223 DichlorideAcetyldigitoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.
RaltitrexedAcetyldigitoxin may decrease the cardiotoxic activities of Raltitrexed.
RamucirumabAcetyldigitoxin may decrease the cardiotoxic activities of Ramucirumab.
RanibizumabAcetyldigitoxin may decrease the cardiotoxic activities of Ranibizumab.
RanpirnaseAcetyldigitoxin may decrease the cardiotoxic activities of Ranpirnase.
RegorafenibAcetyldigitoxin may decrease the cardiotoxic activities of Regorafenib.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Acetyldigitoxin.
ResveratrolAcetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.
Rhodamine 6GAcetyldigitoxin may decrease the cardiotoxic activities of Rhodamine 6G.
RibostamycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Ribostamycin.
RituximabAcetyldigitoxin may decrease the cardiotoxic activities of Rituximab.
RomidepsinAcetyldigitoxin may decrease the cardiotoxic activities of Romidepsin.
RomiplostimAcetyldigitoxin may decrease the cardiotoxic activities of Romiplostim.
RoquinimexAcetyldigitoxin may decrease the cardiotoxic activities of Roquinimex.
RubitecanAcetyldigitoxin may decrease the cardiotoxic activities of Rubitecan.
RuxolitinibAcetyldigitoxin may decrease the cardiotoxic activities of Ruxolitinib.
SatraplatinAcetyldigitoxin may decrease the cardiotoxic activities of Satraplatin.
SeliciclibAcetyldigitoxin may decrease the cardiotoxic activities of Seliciclib.
SemaxanibAcetyldigitoxin may decrease the cardiotoxic activities of Semaxanib.
SeocalcitolAcetyldigitoxin may decrease the cardiotoxic activities of Seocalcitol.
SiltuximabAcetyldigitoxin may decrease the cardiotoxic activities of Siltuximab.
SirolimusAcetyldigitoxin may decrease the cardiotoxic activities of Sirolimus.
SonidegibAcetyldigitoxin may decrease the cardiotoxic activities of Sonidegib.
SorafenibAcetyldigitoxin may decrease the cardiotoxic activities of Sorafenib.
SotalolSotalol may increase the bradycardic activities of Acetyldigitoxin.
SparfloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Sparfloxacin.
Sparfosic acidAcetyldigitoxin may decrease the cardiotoxic activities of Sparfosic acid.
SparsomycinAcetyldigitoxin may decrease the cardiotoxic activities of Sparsomycin.
SpectinomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Spectinomycin.
SpironolactoneThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Spironolactone.
squalamineAcetyldigitoxin may decrease the cardiotoxic activities of squalamine.
SRT501Acetyldigitoxin may decrease the cardiotoxic activities of SRT501.
StreptomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Streptomycin.
StreptozocinAcetyldigitoxin may decrease the cardiotoxic activities of Streptozocin.
StreptozocinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Streptozocin.
SulfasalazineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Sulfasalazine.
SulindacAcetyldigitoxin may decrease the cardiotoxic activities of Sulindac.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigitoxin.
SunitinibAcetyldigitoxin may decrease the cardiotoxic activities of Sunitinib.
SuraminAcetyldigitoxin may decrease the cardiotoxic activities of Suramin.
SwainsonineAcetyldigitoxin may decrease the cardiotoxic activities of Swainsonine.
TamoxifenAcetyldigitoxin may decrease the cardiotoxic activities of Tamoxifen.
TegafurAcetyldigitoxin may decrease the cardiotoxic activities of Tegafur.
TelmisartanThe serum concentration of Acetyldigitoxin can be increased when it is combined with Telmisartan.
TemafloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Temafloxacin.
TemozolomideAcetyldigitoxin may decrease the cardiotoxic activities of Temozolomide.
TemsirolimusAcetyldigitoxin may decrease the cardiotoxic activities of Temsirolimus.
TeniposideAcetyldigitoxin may decrease the cardiotoxic activities of Teniposide.
TestolactoneAcetyldigitoxin may decrease the cardiotoxic activities of Testolactone.
TetrathiomolybdateAcetyldigitoxin may decrease the cardiotoxic activities of Tetrathiomolybdate.
TezacitabineAcetyldigitoxin may decrease the cardiotoxic activities of Tezacitabine.
ThalidomideAcetyldigitoxin may decrease the cardiotoxic activities of Thalidomide.
ThiotepaAcetyldigitoxin may decrease the cardiotoxic activities of Thiotepa.
ThymalfasinAcetyldigitoxin may decrease the cardiotoxic activities of Thymalfasin.
TiboloneAcetyldigitoxin may decrease the cardiotoxic activities of Tibolone.
TimololTimolol may increase the bradycardic activities of Acetyldigitoxin.
TioguanineAcetyldigitoxin may decrease the cardiotoxic activities of Tioguanine.
TipifarnibAcetyldigitoxin may decrease the cardiotoxic activities of Tipifarnib.
TirapazamineAcetyldigitoxin may decrease the cardiotoxic activities of Tirapazamine.
TobramycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Tobramycin.
TopotecanAcetyldigitoxin may decrease the cardiotoxic activities of Topotecan.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin.
ToremifeneAcetyldigitoxin may decrease the cardiotoxic activities of Toremifene.
TositumomabAcetyldigitoxin may decrease the cardiotoxic activities of Tositumomab.
TrabectedinAcetyldigitoxin may decrease the cardiotoxic activities of Trabectedin.
TrametinibAcetyldigitoxin may decrease the cardiotoxic activities of Trametinib.
TrastuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.
Trastuzumab emtansineAcetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab emtansine.
TretinoinAcetyldigitoxin may decrease the cardiotoxic activities of Tretinoin.
TriamtereneThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin.
TrifluridineAcetyldigitoxin may decrease the cardiotoxic activities of Trifluridine.
TrilostaneAcetyldigitoxin may decrease the cardiotoxic activities of Trilostane.
TrimetrexateAcetyldigitoxin may decrease the cardiotoxic activities of Trimetrexate.
TriptorelinAcetyldigitoxin may decrease the cardiotoxic activities of Triptorelin.
TrovafloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Trovafloxacin.
TroxacitabineAcetyldigitoxin may decrease the cardiotoxic activities of Troxacitabine.
TTNPBAcetyldigitoxin may decrease the cardiotoxic activities of TTNPB.
TubercidinAcetyldigitoxin may decrease the cardiotoxic activities of Tubercidin.
UbenimexAcetyldigitoxin may decrease the cardiotoxic activities of Ubenimex.
Uracil mustardAcetyldigitoxin may decrease the cardiotoxic activities of Uracil mustard.
ValrubicinAcetyldigitoxin may decrease the cardiotoxic activities of Valrubicin.
VandetanibAcetyldigitoxin may decrease the cardiotoxic activities of Vandetanib.
VapreotideAcetyldigitoxin may decrease the cardiotoxic activities of Vapreotide.
VeliparibAcetyldigitoxin may decrease the cardiotoxic activities of Veliparib.
VemurafenibAcetyldigitoxin may decrease the cardiotoxic activities of Vemurafenib.
VerteporfinAcetyldigitoxin may decrease the cardiotoxic activities of Verteporfin.
VinblastineAcetyldigitoxin may decrease the cardiotoxic activities of Vinblastine.
VincristineAcetyldigitoxin may decrease the cardiotoxic activities of Vincristine.
VindesineAcetyldigitoxin may decrease the cardiotoxic activities of Vindesine.
VinorelbineAcetyldigitoxin may decrease the cardiotoxic activities of Vinorelbine.
VismodegibAcetyldigitoxin may decrease the cardiotoxic activities of Vismodegib.
Vitamin AAcetyldigitoxin may decrease the cardiotoxic activities of Vitamin A.
VorinostatAcetyldigitoxin may decrease the cardiotoxic activities of Vorinostat.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Gonzalez-Garcia C, Cena V, Klein DC: Characterization of the alpha +-like Na+,K+-ATPase which mediates ouabain inhibition of adrenergic induction of N-acetyltransferase (EC 2.3.1.87) activity: studies with isolated pinealocytes. Mol Pharmacol. 1987 Dec;32(6):792-7. [PubMed:2826993 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23